TABLE 1.

Summary of EAE Clinical Characteristics

	Strain	Incidence	Mortality	Weight at immunization	Day of onset	Maximum clinical scorea	Cumulative clinical scoreb	Relapse ratec
Expt. 1	SJL
Control		10/10	7/9 (77%)	19.5 ± 0.9d	11.2 ± 0.6	5 (4–5)	NA	NA
HF		10/10	7/10 (70%)	22.2 ± 2.7d	11.6 ± 0.8	5 (2.5–5)	NA	NA
CR		9/10	2/10 (20%)e	15.7 ± 2d	11.1 ± 1.1	4 (0–5)f	NA	NA
Expt. 2	SJL
Control		13/13	5/13 (38%)	18.6 ± 0.9g	10.7 ± 0.9	4 (3–5)	29.4 ± 18	1.7
HF		12/12	5/12 (41%)	21.3 ± 1.6g	11.5 ± 1.6	4.2 (3.5–5)	30.8 ± 5.6	1.1
CR		11/11	3/11 (27%)	12.4 ± 0.6g	20.5 ± 4.6h	4 (3–5)	18.8 ± 10	0.5
Expt. 3	SJL
Control		11/11	0/11	18.4 ± 0.9	12.7 ± 1.3	4 (3–4)	45.8 ± 10.1	NA
							(45.8 ± 80.7)
CR		7/11	0/11	13.4 ± 0.8i	15.5 ± 3.4j	2.5 (0–4)k	19.5 ± 17.2l	NA
							(30.7 ± 9.8)j
Expt. 4	C57BL/6J
Control		9/9	4/9 (44%)	19 ± 0.7	12.7 ± 4.3	4 (3.5–5)	44.3 ± 11.7	NR
							(44.3 ± 11.7)
CR		8/9	2/9 (22%)	13.5 ± 0.4i	18.1 ± 4.3m	3.5 (0–5)	22.2 ± 15.4j	NR
							(25.9 ± 13)n

Values are means ± sd; 

^amedian (range); 

^bcumulative clinical score calculated over the first 30 days for all mice or only sick mice (given in parentheses)/group; 

^caverage number of relapses per mouse; 

^dExpt. 1, P < 0.05 for control versus HF; P < 0.01 for control versus CR, and P < 0.001 for CR versus HF; ANOVA with Tukey’s multiple comparison test; 

^eP = 0.02 CR versus control death rate by χ²; 

^fCR versus control; P < 0.05, Kruskal-Wallis; 

^gExp. 2, P < 0.001 for weights in each group compared with each other group; ANOVA with Tukey’s multiple comparison test; 

^hCR is greater than HF and control P < 0.001; ANOVA with Tukey’s multiple comparison test; 

ⁱP < 0.0001 by t-test; 

^jP = 0.02 by t-test; 

^kP = 0.08 by Mann-Whitney U test; 

^lP = 0.003 by t-test; 

^mP = 0.01 by t-test; 

ⁿP = 0.03 by t-test. NA, Not available because of high mortality early during the experiment or because follow-up was only 30 days p.i.; NR, non relapsing.